BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37948318)

  • 21. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway.
    Lin KN; Jiang YL; Zhang SG; Huang SY; Li H
    Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
    Lewis NR; Pallis M; Russell NH
    Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
    Jin J; Li X; Guo W; Li F; Huang J; Huang X; Pan J; Huang S; Ye W; Ling Q; Jin J
    Oncol Rep; 2020 Jul; 44(1):273-282. PubMed ID: 32626988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway.
    Zhang X; Yang L; Liu X; Nie Z; Liu M; Wang T; Lu Y; Pan Y; Zhan Y; Wang Z; Luo J
    Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119607. PubMed ID: 37852323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
    Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
    Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.
    Liu Y; Chen Y; Liu Y; Li M; Zhang Y; Shi L; Yang L; Li T; Li Y; Jiang Z; Liu Y; Wang C; Wang S
    J Transl Med; 2022 Dec; 20(1):612. PubMed ID: 36550462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
    Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
    Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
    Chen L; Li D; Guo X; Cheng C; Wei X
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.
    Guo D; Xu P; Chen D; Wang L; Zhu Y; Zuo Y; Chen B
    Int J Nanomedicine; 2020; 15():521-536. PubMed ID: 32021192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.
    Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
    J Cell Biochem; 2020 Jan; 121(1):385-393. PubMed ID: 31222822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTSB Knockdown Inhibits Proliferation and Tumorigenesis in HL-60 Cells.
    Peng S; Yang Q; Li H; Pan Y; Wang J; Hu P; Zhang N
    Int J Med Sci; 2021; 18(6):1484-1491. PubMed ID: 33628106
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of Long Non-Coding RNA LINC01268 on the Malignant Biological Behaviors of Acute Myeloid Leukemia Cells].
    Chen W; Gan DY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1608-1616. PubMed ID: 38071035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
    Tan SF; Dunton W; Liu X; Fox TE; Morad SAF; Desai D; Doi K; Conaway MR; Amin S; Claxton DF; Wang HG; Kester M; Cabot MC; Feith DJ; Loughran TP
    J Lipid Res; 2019 Jun; 60(6):1078-1086. PubMed ID: 30962310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway.
    Zhang R; Tang P; Wang F; Xing Y; Jiang Z; Chen S; Meng X; Liu L; Cao W; Zhao H; Ma P; Chen Y; An C; Sun L
    J Cell Biochem; 2019 Mar; 120(3):4423-4432. PubMed ID: 30367526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
    Ross DD; Wooten PJ; Tong Y; Cornblatt B; Levy C; Sridhara R; Lee EJ; Schiffer CA
    Blood; 1994 Mar; 83(5):1337-47. PubMed ID: 8118035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Combination of Flavokawain B and Daunorubicin Induces Apoptosis in Human Myeloid Leukemic Cells by Modifying NF-κB.
    Lee JJ; Koh KN; Park CJ; Jang S; Im HJ; Kim N
    Anticancer Res; 2018 May; 38(5):2771-2778. PubMed ID: 29715098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
    Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
    Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.
    Angenendt L; Wöste M; Mikesch JH; Arteaga MF; Angenendt A; Sandmann S; Berdel WE; Lenz G; Dugas M; Meshinchi S; Schliemann C; Rössig C
    Blood Adv; 2021 Nov; 5(21):4413-4421. PubMed ID: 34559198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.